← All trials
NCT04695704
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2021
- Primary completion
- Mar 31, 2022
- Completion date
- Dec 31, 2022
- First posted
- Jan 5, 2021
- Last posted
- Jan 5, 2021
- Enrollment
- 284
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Jordi Gol i Gurina FoundationLead sponsor
- Institut Català de la SalutStudy chair
- Institut Català de la SalutOverall official - principal investigator
- Institut Català de la SalutCollaborator
- Jordi Gol i Gurina FoundationStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.